A threesome on drugs: talking $BMYRT with Matt and Dan episode artwork

EPISODE · Sep 14, 2020 · 1H 19M

A threesome on drugs: talking $BMYRT with Matt and Dan

from Yet Another Value Podcast · host Andrew Walker

Matt Turk and Dan Schneeberger do an extremely deep dive into BMYRT. BMYRT is a contingent value right (CVR) established when Bristol-Myers Squibb (BMY) bought Celgene. While CVR's are extremely risky and there is a real chance of this proving worthless, Matt and Dan walk through what a CVR is, why a CVR might be overlooked, and why they think the odds of approval for the drugs underlying BMY's CVR are much higher than the market suggests.Again, CVRs are risky, and nothing in this podcast is investing advice.Twitter handles: Matt: Given2Tweet (https://twitter.com/given2tweet)Dan: Sheep of Wall Street (https://twitter.com/Biohazard3737)

Episode metadata supplied by the publisher feed · Published Sep 14, 2020

Embed this episode

Ready to play

A threesome on drugs: talking $BMYRT with Matt and Dan

0:00 1:19:16

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Yet Another Value Podcast?

This episode is 1 hour and 19 minutes long.

When was this Yet Another Value Podcast episode published?

This episode was published on September 14, 2020.

Can I download this Yet Another Value Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!